iShares MSCI France ETF vs Eli Lilly And Co — how do they compare? iShares MSCI France ETF trades at $47.49, while Eli Lilly And Co trades at $1,220.55 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals.
| EWQ | LLY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $1.24K |
52-Week Low | $41.68 | $639.43 |
Market Cap | — | $1.08T |
Enterprise Value | — | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
EWQ, the iShares MSCI France ETF, trades at $47.54, down 0.44% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is concentrated in industrials and benefits from positive momentum in European equities, with a dividend scheduled for June 2026. Recent news highlights France's tech investments and ECB rate decisions influencing regional economic sentiment.
The outlook for EWQ is supported by favorable European market trends and institutional interest, though risks include geopolitical tensions affecting energy prices and potential ECB tightening. Investors should weigh the ETF's exposure to French equities against macroeconomic headwinds for balanced positioning.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Trailing returns across standard periods
Latest headlines on both assets
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →